---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-277030"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:08:42.792399+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DBV Technologies Q3 net loss $17.3M; cash $213M; VITESSE Phase 3 delayed by clinical hold

## Summary
- Q3 net loss of $17.3M ($0.18 per share); nine-month net loss $57.0M ($0.79 per share).
- Cash and cash equivalents $212.7M as of Sept 30, 2022, up from $77.3M at Dec 31, 2021.
- Operating expenses decreased 22% in Q3 and 26% in first nine months vs prior year.
- Partial clinical hold on VITESSE Phase 3 study; first patient screen not expected by year-end 2022.
- Cash used in operating activities fell 35% YoY; cost containment measures cited.

## SEC filing metadata
- accession: 0001193125-22-277030
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/0001193125-22-277030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/d411212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-277030
- JSON: https://secwatch.observer/filing/0001193125-22-277030.json
- Plain text: https://secwatch.observer/filing/0001193125-22-277030.txt

## Key facts
- Earnings Releases
  DBV Technologies S.A. reported the third quarter of 2022 results: net income $(17.3) million, EPS $(0.18).
  - Period: the third quarter of 2022
  - Net income: $(17.3) million
  - EPS: $(0.18)
  - Result: reported results
  source text: DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/0001193125-22-277030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.